

## December 2022

### Policy and submissions

- NADA welcomed the NSW Government response to the Special Commission of Inquiry into the Drug 'Ice' in a [media release](#) [PDF].
- Australian Alcohol and other Drugs Council (AADC) wrote to Minister Mark Butler to raise key issues including quantum of core funding, indexation, contract length, national governance and implications of the foreshadowed statutory price reductions to ODTP medications,
- NADA produced an [election issues](#) [PDF] paper to highlight key challenges facing the sector and the actions required and invited the NSW election candidates to respond.
- NADA drafted a position paper on 'Measuring performance of NSW non government AOD treatment services', which summarises the 'Performance measurement study' and recommendations.

### Advocacy and representation

- NADA Chair, CEO and Deputy CEO met with Minister Hazzard to discuss the participation of NADA and the sector in development of a whole of government AOD strategy and process for the distribution of funds to increase the sector's capacity to meet demand.
- NADA CEO and Deputy CEO met with representatives of the DoHA ATOD Branch, NIAA and the NSW/ACT PHN CEOs network to discuss the 'Performance measurement study' and implementation of the core set of indicators by all funders of NGO AOD contracts in NSW. NADA CEO presented on the study at the Lisbon Addictions Conference.
- The Ministry of Health CAOD provided a webinar to members on the government response to the Special Commission of Inquiry.
- NADA CEO was invited to be on panel at the NCOSS Conference to discuss NGO workforce challenges; and was invited to be on a panel at the ADARRN Symposium to discuss NGO funding issues.
- NADA continues to represent the sector with key stakeholders: NSW Ministry of Health COVID-19 Clinical Council Meeting; Department of Health and Aged Care; DSS Community Grants Hub; ASU; NUAA; FDS; AADC; State and Territory Peaks Network; NCOSS; NCCRED; ACDAN; ADARRN; DACRIN; AOD Peaks network; PHN AOD Network and PHN CEO Network.
- Ongoing meeting representation: NSW Ministry of Health COVID-19 Clinical Council; DAPC, ACI D&A Executive Committee; NGO AOD Reference Group, Stigma and Discrimination Steering Committee, MOH Naloxone Advisory Group, Virtual Care Working Group, Safe Side Program Planning, Hepatitis C Strategy Implementation Committee; NCOSS Health Equity Alliance; NCOSS FONGA; Justice Reform Initiative; CDAT Advisory Group; NSW Ministry of Health AOD Quality in Treatment and more.

Information on NADA's policy and advocacy work, including Sector Watch and the meetings that NADA represents its members, is available on the NADA website [here](#).